Measuring quality of life using patient-reported outcomes in real-world metastatic breast cancer patients: The need for a standardized approach

Marloes E. Clarijs, Jacob Thurell, Friedrich Kühn, Carin A. Uyl-De Groot, Elham Hedayati, Maria M. Karsten, Agnes Jager, Linetta B. Koppert*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

3 Citations (Scopus)
3 Downloads (Pure)

Abstract

Metastatic breast cancer (MBC) patients are almost always treated to minimize the symptom burden, and to prolong life without a curative intent. Although the prognosis of MBC patients has improved in recent years, the median survival after diagnosis is still only 3 years. Therefore, the health-related quality of life (HRQoL) should play a leading role in making treatment decisions. Heterogeneity in questionnaires used to evaluate the HRQoL in MBC patients complicates the interpretability and comparability of patient-reported outcomes (PROs) globally. In this review, we aimed to provide an overview of PRO instruments used in real-world MBC patients and to discuss important issues in measuring HRQoL. Routinely collecting symptom information using PROs could enhance treatment evaluation and shared decision-making. Standardizing these measures might help to improve the implementation of PROs, and facilitates collecting and sharing data to establish valid comparisons in research. This is a prerequisite to learn about how they could impact the clinical care pathway. In addition, the prognostic value of intensified PRO collection throughout therapy on survival and disease progression is promising. Future perspectives in the field of PROs and MBC are described.

Original languageEnglish
Article number2308
JournalCancers
Volume13
Issue number10
DOIs
Publication statusPublished - 12 May 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Fingerprint

Dive into the research topics of 'Measuring quality of life using patient-reported outcomes in real-world metastatic breast cancer patients: The need for a standardized approach'. Together they form a unique fingerprint.

Cite this